Vol 28, No 3 (2021)
Research Letter
Published online: 2021-03-10
Monitoring of QTc interval in patients with COVID-19. First experience with a portable ECG-recording device
Abstract
Not available
References
- Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20): 1881–1890.
- Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006; 44(2): 173–175.
- Anson B, Weaver J, Ackerman M, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005; 365(9460): 682–686.
- Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006; 47(2): 362–367.
- Chang D, Saleh M, Gabriels J, et al. Inpatient use of ambulatory telemetry monitors for COVID-19 patients treated with hydroxychloroquine and/or azithromycin. J Am Coll Cardiol. 2020; 75(23): 2992–2993.
- Guerrero LR, Ongay AG, Álvarez ÁC, et al. Protocolo de manejo hospitalario de alteraciones electrocardiográficas en pacientes con COVID-19 con un sistema portátil vinculado a smartphone. REC: CardioClinics. 2020; 55(3): 192–195.
- Strik M, Caillol T, Ramirez FD, et al. Validating QT-interval measurement using the apple watch ECG to enable remote monitoring during the COVID-19 pandemic. Circulation. 2020; 142(4): 416–418.
